Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
Myriad Genetics (NASDAQ: MYGN), a molecular diagnostic testing and precision medicine company, has scheduled its second quarter 2025 earnings release and conference call for August 5, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN), a molecular diagnostic testing and precision medicine company, has scheduled its second quarter 2025 earnings release and conference call for August 5, 2025. The financial results will be released after market close, followed by a conference call at 4:30 PM ET.
Management will discuss the company's Q2 2025 financial performance and provide a business update during the call. Investors can access the live webcast through Myriad's Investor Relations website, while those preferring telephone participation must register to receive dial-in details.
Details
News Market Reaction – MYGN
The recorded move for MYGN in the trading session of this news was -1.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter 2025.
A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.